Astellas, Janssen End Pact for JAK Inhibitor

Astellas Pharma Inc. reports that its license agreement with Janssen Biotech, Inc. to develop and commercialize ASP015K, Astellas' oral Janus Kinase (JAK) inhibitor, will end effective January 15, 2015. Janssen has exercised its right to terminate the license agreement, which was signed in 2012.

Upon the effective date of termination, Astellas will regain all rights granted to Janssen. Astellas is now considering the future plan for ASP015K outside Japan, but will continue the Phase III development program that was initiated in Japan.

Source: Astellas Pharma

Leave a Reply

Your email address will not be published. Required fields are marked *